Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Analysts are bullish on ATE

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Feb 04, 2021 10:14am

204 Views

Post# 32469528

RE:RE:RE:RE:Analysts are bullish on ATE

the thing is the established firm company x nsaid sales will plumet if your competitor company y (bayer) buys out ATE with it's game changing drug that makes all other nsaid drugs obsolete, if in fact the drug turns out as good as we think. all other drug makers better act fast the clock is ticking (bidding war) lol

<< Previous

Bullboard Posts

Next >>

Meet Canopy USA’s new CEO, Brooks Jorgensen